Semaglutide linked to ischemic colitis in a 53-year-old woman without traditional vascular risk factors
Background
Ischemic colitis (IC) is a condition characterized by reduced blood flow to the colon, typically affecting individuals with pre-existing vascular risk factors like atherosclerosis, heart disease, or diabetes. However, a significant portion of cases remain idiopathic. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide are increasingly prescribed for type 2 diabetes mellitus and obesity, known for their efficacy and generally favorable safety profile, though gastrointestinal side effects are common. This case highlights a potential, rare adverse event in an atypical patient population, challenging the usual understanding of IC etiology.
Study Design
This case report details a 53-year-old woman with no significant medical history or traditional vascular risk factors who developed acute abdominal pain and haematochezia after initiating semaglutide. The specific dose or duration of semaglutide prior to symptom onset was not detailed in the abstract. Diagnostic evaluation included imaging (likely CT scan), colonoscopy, and biopsy to confirm the diagnosis of ischemic colitis. An infectious workup was also performed to rule out other causes of colitis, serving as a crucial differential diagnostic step.
Results
Upon presentation, the 53-year-old woman exhibited acute abdominal pain and haematochezia, symptoms highly suggestive of gastrointestinal distress. Comprehensive diagnostic procedures, including imaging, colonoscopy, and biopsy, definitively confirmed the diagnosis of ischemic colitis. Importantly, an infectious workup yielded negative results, effectively ruling out common infectious etiologies for colitis. The patient's symptoms completely resolved following the discontinuation of semaglutide and the initiation of supportive care, strongly suggesting a direct association. This outcome underscores the potential for GLP-1RAs to induce ischemic colitis even in individuals without the typical predisposing vascular risk factors. The resolution of symptoms post-discontinuation provides compelling evidence for drug-induced etiology.
Symptoms resolved completely following discontinuation of semaglutide and supportive care, confirming the drug's role in the ischemic colitis.
Key Findings
- A 53-year-old woman without vascular risk factors developed acute abdominal pain and haematochezia after initiating semaglutide.
Imaging,colonoscopy, andbiopsyconfirmed the diagnosis of ischemic colitis.- An
infectious workupfor colitis was negative, ruling out common alternative causes. - Symptoms resolved completely after semaglutide discontinuation and supportive care.
- The case suggests a potential association between GLP-1RAs and ischemic colitis in atypical patients.
Why It Matters
This case report significantly impacts clinical practice by highlighting a rare but serious adverse event associated with semaglutide and other GLP-1RAs. For clinicians, it necessitates a heightened index of suspicion for ischemic colitis in patients presenting with new-onset abdominal pain and haematochezia while on these medications, even in the absence of traditional vascular risk factors. Early recognition and prompt discontinuation of the GLP-1RA are crucial for complete clinical recovery, potentially preventing more severe outcomes. This finding suggests that the safety profile of GLP-1RAs might include rare idiosyncratic reactions, warranting careful patient monitoring. While this is a single case, it adds to the growing body of post-marketing surveillance data that informs safer prescribing practices.
semaglutide
ischemic-colitis
adverse-event
glp-1-agonist
case-report
gastrointestinal